



**PARIS
MASH
MEETING**

2025 PROGRAM

**11TH EDITION
SEPTEMBER 11 & 12 2025**

 **INSTITUT
PASTEUR**

With the partnership of



Organized by

Arun Sanyal

Virginia Commonwealth
University School of Medicine,
Richmond, Virginia, USA

Lawrence Serfaty

Nouvel Hôpital Civil
Hôpitaux Universitaires de Strasbourg,
Strasbourg, France

Scientific committee

Jérôme Boursier
Jean-François Dufour
Scott Friedman
Fabio Marra
Veronica Miller
Massimo Pinzani
Vlad Ratziu
Jörn Schattenberg
Mohammad S. Siddiqui



**PARIS
MASH
MEETING**



EDITORIAL

As the **11th edition of the Paris MASH Meeting** unfolds, we continue to push the boundaries of **metabolic health research**.

This year, the spotlight turns to the integration of **Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)** in to the **noncommunicable disease spectrum** and its broader implications on global health.

Our program delves into the latest advances in **epidemiology, clinical trials, and translational science**, with a particular focus on **cancer risk, miRNA research, and therapeutic innovations**.

By bringing together **leading international experts**, we aim to foster **cutting-edge discussions and collaborative breakthroughs**.

Join us at the prestigious **Institut Pasteur on September 11-12, 2025**, to explore the future of **MASLD care and research**.

Arun Sanyal & Lawrence Serfaty



PARIS MASH MEETING

September 11 & 12, 2025, Institut Pasteur

SCIENTIFIC PROGRAM

International Think Tank

THURSDAY, 11 SEPTEMBER

08:30 - 08:55 AM **WELCOME DESK OPENING**

08:55 - 09:00 AM **Introduction**
Lawrence Serfaty (France)

SESSION 1: EPIDEMIOLOGY AND PUBLIC HEALTH

Chairs: Arun Sanyal (USA), Massimo Pinzani (UK)

09:00 - 09:15 AM **Does MASLD contribute to the overall burden of cancer and cancer-related mortality ?**
Homi Razavi (USA)

09:15 - 09:30 AM **Implications of global policies on noncommunicable diseases for patients with MASLD**
Shiv Kumar Sarin (India)

09:30 - 09:45 AM **Age-dependent comorbidity profiles and genetic disorders in real world MASLD cohorts**
Stefano Romeo (Sweden)

09:45 - 10:15 AM **Discussion**

10:15 - 10:45 AM **COFFEE BREAK AND POSTERS**

SESSION 2: CLINICAL FRONTIERS

Chairs: Jean-François Dufour (Switzerland), Lawrence Serfaty (France)

10:45 - 11:00 PM **Inclusion of cancer screening within MASLD treatment guidelines**
Jérôme Boursier (France)

11:00 - 11:15 PM **Do patients with MASH develop post-transplant cancers with greater frequency ?**
Christophe Moreno (Belgium)

11:15 - 11:30 PM **Relevance of MASLD/MASH on kidney transplantation**
Gaurav Gupta (USA)

11:30 - 12:00 PM **Discussion**

12:00 - 01:00 PM **INDUSTRY SYMPOSIUM**

PARALLEL LUNCH SESSION

01:00 - 02:45 PM **1 - Assessment of competing risks to guide individualized risk based management strategies in the clinic**
Michael Roden (Germany) and Vlad Ratziu (France)

01:00 - 02:45 PM **2 - Imaging in MASLD: from diagnosis to monitoring**
Cyrielle Caussy (France) and Jörn Schattenberg (Germany)

01:00 - 02:45 PM **3 - Clinical Trial Update**
Mary Rinella (USA) and Raluca Pais (France)



PARIS MASH MEETING

September 11 & 12, 2025, Institut Pasteur

SCIENTIFIC PROGRAM

International Think Tank

SESSION 3: CLINICAL HOT TOPICS

Chairs: Fabio Marra (Italy) and Stanislas Pol (France)

- 02:45 - 03:00 PM **MASH as a driver of colorectal cancer and cancer metastasis**
Ekihiro Seki (USA)
- 03:00 - 03:15 PM **Hypobetalipoproteinemia and the risk of HCC in the general population**
Bertrand Cariou (France)
- 03:15 - 03:30 PM **Is tumor-associated fibrosis harmful or beneficial in MASH-HCC?**
Scott Friedman (USA)
- 03:30 - 04:00 PM **Discussion**

04:00 - 04:30 PM COFFEE BREAK AND POSTERS

- 04:30 - 05:00 PM **BASIC SCIENCE LECTURE**
Mechanistic implications of MASLD as etiology of HCC on checkpoint inhibitor therapies
Chair: Lawrence Serfaty (France)
Peter Galle (Germany)

SESSION 4: TRANSLATIONAL SCIENCE-miRNA

Chairs: Scott Friedman (USA), Frank Tacke (Germany)

- 05:00 - 05:15 PM **RNA isotypes and their relevance in MASLD**
Stephen Hoang (USA)
- 05:15 - 05:30 PM **miRNA and intrahepatic cell-cell cross talk in MASH progression**
Pierre-Emmanuel Rautou (France)
- 05:30 - 05:45 PM **miRNA and inter-organ cross-talk in MASLD-metabolic syndrome**
Saumya Das (USA)
- 05:45 - 06:15 PM **Discussion**

06:15 - 06:25 PM POSTER AWARD SESSION



PARIS MASH MEETING

September 11 & 12, 2025, Institut Pasteur

SCIENTIFIC PROGRAM

International Think Tank

FRIDAY, 12 SEPTEMBER

08:30 - 09:30 AM **SESSION 5: INDUSTRY CORNER**

Chairs : Arun Sanyal (USA), Lawrence Serfaty (France)

Presentations & Round table

09:30 - 10:00 AM **COFFEE BREAK AND POSTERS**

SESSION 6: CLINICAL TRIALS

Chairs: Mary Rinella (USA), Vlad Ratziu (France)

10:00 - 10:15 AM **Integrated Trial Design - challenges and opportunities for MASLD to be included in CRM trials**

Faiez Zannad (France)

10:15 - 10:30 AM **What is the evidence needed to extend label indication for approved MASH therapies to children ?**

Johannes Taminiau (Belgium)

10:30 - 10:45 AM **Design of trials in real-world setting to establish value of MASH therapies**

Natalia Muhlemann (USA)

10:45 - 11:15 PM **Discussion**

11:15 - 12:15 AM **INDUSTRY SYMPOSIUM**

PARALLEL LUNCH SESSION

12:15 - 02:00 PM **1 - MASLD as a DILI risk factor**

Jean-François Dufour (Switzerland) and TBD

12:15 - 02:00 PM **2 - Integrating metabolic to alcohol driven spectrum of steatotic liver disease for clinical care**

Philippe Mathurin (France) and Michael Lucey (USA)

12:15 - 02:00 PM **3 - Clinical Challenges**

Laurent Castera (France) and Maud Lemoine (UK)

REGULATORY FORUM SYMPOSIUM

Chair: Lawrence Serfaty (France)

02:00 - 02:15 PM **A progress report on the placebo arm project of the Liver Forum**

Veronica Miller (USA)

02:15 - 02:30 PM **FNIH Corner**

Tania Kamphaus (USA)



PARIS MASH MEETING

September 11 & 12, 2025, Institut Pasteur

SCIENTIFIC PROGRAM

International Think Tank

02:30 - 03:00 PM **CLINICAL LECTURE**
Progress in development of a reasonably likely surrogate endpoint for MASH
Chair: Laurent Castera (France)
Arun Sanyal (USA)

SESSION 7: MAKING MASLD CARE UNIVERSAL - THE GLOBAL HEALTH CORNER
Chair: Arun Sanyal (USA)

03:00 - 03:15 PM **How Latin America is retraining its workforce to manage MASLD**
David Kershenobich (Mexico)

03:15 - 03:30 PM **Status of MASLD in the UN policy summit on resource allocation for non-communicable diseases**
Johanna Ralston (World Obesity Federation)

03:30 - 03:45 PM **Role of Journals in increasing awareness and changing practice for MASLD**
Ben Abbott (Executive Editor, The Lancet)

03:45 - 04:00 PM **Round table**

04:00 - 04:10 PM **CONCLUDING REMARKS**



PARIS MASH MEETING

September 11 & 12, 2025, Institut Pasteur

SCIENTIFIC PROGRAM

International Think Tank

FACULTY 2025

ABBOTT Ben

BOURSIER Jérôme

CARIOU Bertrand

CASTERA Laurent

CAUSSY Cyrielle

DAS Saumya

DUFOUR Jean-François

FRIEDMAN Scott

GALLE Peter

DE OLIVEIRA GERALDES Flavia

GUPTA Gorav

HOANG Stephen

KAMPHAUS Tania

KERSHENOBICH David

LEMOINE Maud

LUCEY Michael

MARRA Fabio

MATHURIN Philippe

MILLER Veronica

MORENO Christophe

MUHLEMANN Natalia

PAIS Raluca

PINZANI Massimo

POL Stanislas

RALSTON Johanna

RAUTOU Pierre-Emmanuel

RAZAVI Homie

RATZIU Vlad

RINELLA Mary

RODEN Michael

ROMEO Stefano

SANYAL Arun

SARIN Shiv Kumar

SCHATTENBERG Jörn

SEKI Ekihiro

SERFATY Lawrence

TACKE Frank

TAMINIAU Johannes

ZANNAD Faiez